Retatrutide: Triple-Receptor Activation, Phase 3 Pending

The short version

Retatrutide (also called LY3437943) is an investigational 39-amino-acid peptide designed to activate three hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide receptor), GLP-1 (glucagon-like peptide-1 receptor), and the glucagon receptor. Adding the glucagon arm to the dual GIP/GLP-1 agonism found in other incretin-class compounds is what distinguishes it — glucagon receptor activation adds energy expenditure and lipid mobilization on top of the appetite suppression and insulin-sensitization produced by the other two ^[1].

In a 48-week Phase 2 trial in adults with obesity, retatrutide at 12 mg once weekly produced a mean body-weight reduction of 24.2% versus 2.1% with placebo ^[4]. In a parallel Phase 2 trial in type 2 diabetes, the 12 mg group achieved an HbA1c reduction of 2.02% at 24 weeks and a 16.94% body-weight reduction at 36 weeks ^[5]. These are trial results in supervised clinical settings — not general-use outcomes. Retatrutide is not approved by any regulator as of mid-2026. Phase 3 TRIUMPH trials are underway. This page reports the research; it is not medical advice and lists no human dose.

What it is

Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone, with a C20 fatty-diacid conjugated to enable albumin binding and extend its half-life — the same acylation strategy used to achieve once-weekly dosing. Its molecular formula in free-acid form is C221H342N46O68.

The research shorthand LY3437943 (Eli Lilly's compound number) is the identifier used in trial registrations. The compound is sometimes called a GGG tri-agonist or triple-incretin-receptor agonist in the literature ^[2]. It is an investigational drug, not available as a prescription product outside clinical trials, and not available as an approved consumer medication.

How it works

Cryo-electron microscopy structures resolved retatrutide engaging all three receptor complexes — GLP-1R, GIPR, and GCGR — simultaneously ^[2]. Its relative potency at each receptor differs from native hormones: approximately 8.9-fold more potent than native GIP at GIPR, but 0.3-fold and 0.4-fold compared to native glucagon and native GLP-1 at GCGR and GLP-1R respectively. This asymmetry is deliberate — strong GIP agonism enhances glucose-dependent insulin secretion and likely tolerability, while partial glucagon agonism adds metabolic throughput without an unacceptable cardiovascular or glycemic burden ^[2].

In plain terms: the GLP-1 and GIP arms suppress appetite and improve postprandial glucose handling. The glucagon arm adds thermogenic energy expenditure and drives lipid mobilization — the mechanism believed to underlie retatrutide's larger weight-loss magnitude compared to dual or single agonists. Metabolomics and lipidomics from Phase 2 participants confirmed dose-dependent reductions in triglycerides and insulin-resistance biomarkers, with fatty-acid-oxidation-cluster changes mediating 23.2% of the weight-reduction response in non-T2D participants ^[7].

What the research shows

Phase 2 obesity (48 weeks). In 338 adults with obesity, once-weekly retatrutide at 12 mg produced a mean body-weight change of -24.2% versus -2.1% with placebo at 48 weeks. GI adverse events were dose-related and mostly mild-to-moderate; a dose-dependent heart-rate increase peaked around 24 weeks ^[4].

Phase 2 type 2 diabetes (36 weeks). In 281 adults with T2D, retatrutide 12 mg reduced HbA1c by 2.02% at 24 weeks and body weight by 16.94% at 36 weeks versus placebo (-0.01% and -3.00% respectively). Mild-moderate GI events in 35%; no severe hypoglycemia and no deaths ^[5].

Liver fat (MASLD substudy, 24/48 weeks). In 98 participants with obesity/overweight and metabolic-dysfunction-associated steatotic liver disease (MASLD, no T2D), retatrutide 12 mg reduced liver fat by a relative 82.4% at 24 weeks; 86% of participants at that dose reached normal liver-fat levels (<5% by MRI-PDFF). Reductions were sustained to 48 weeks (-86.0% at 12 mg) ^[3].

Phase 1b (12 weeks, T2D). The first-in-human multiple-dose study in 72 adults with T2D established an approximate 6-day half-life supporting once-weekly dosing. Placebo-adjusted weight loss at the highest dose reached -8.96 kg over 12 weeks ^[6].

Structure. Cryo-EM structures showed retatrutide engaging all three receptor complexes with distinct ECL1 conformations at each — a structural basis for its tri-agonism ^[2].

Metabolomics. Post-hoc analysis of two Phase 2 RCTs found dose-dependent reductions in triglycerides enriched in short-chain/saturated acyl chains and improvements in insulin-resistance biomarkers (branched-chain amino acids, 2-hydroxybutyrate, urate), in a direction associated with reduced cardiovascular risk ^[7].

Reported effects, cautions & safety

The following community-reported experiences come from peptide research communities and are anecdotal, not clinical evidence — no verified doses, no clinical oversight.

Frequently reported in community accounts: Strong appetite suppression (community members describe near-complete silencing of intrusive food thoughts — what they call "food noise going quiet"). Rapid and pronounced weight reduction, qualitatively faster than other GLP-1-class experiences. Nausea during initial weeks and dose escalation, peaking 4-8 hours post-injection, diminishing with time.

Commonly reported: Elevated resting heart rate, particularly in the hours after administration, tracking with the dose-dependent increases documented in Phase 2 trials. Increased body warmth or mild thermogenic sensation, attributed in community discussion to glucagon-receptor-mediated thermogenesis. Sulfur burps, constipation, and early fatigue or low energy — all consistent with GI motility slowing and aggressive caloric restriction.

Occasionally reported: Sleep disturbances in the initial weeks. Mood uplift and reduced anxiety around food. Lean-mass concern with rapid weight loss.

Cited safety cautions from the clinical literature:

• Unapproved compound, unverified supply. Retatrutide remains investigational; material sold through gray-market research channels cannot be confirmed as authentic retatrutide at stated concentration. The FDA issued over 50 warning letters to retatrutide vendors in 2025 ^[4].
• GI adverse events. Nausea affected up to 45% of participants at the highest dose in Phase 2 and was the principal driver of the 18% discontinuation rate at that dose level ^[4].
• Heart-rate increase. Mean resting heart rate rose approximately 5-7 bpm at highest doses, peaking around 24 weeks; individuals with pre-existing arrhythmias or cardiovascular disease face unmonitored risk ^[4][1].
• Hypoglycemia with insulin or sulfonylureas. Combined GLP-1/GIP agonism can drive blood glucose below safe thresholds in the context of exogenous insulin or sulfonylurea medications ^[5][6].
• Lean-mass loss. A body-composition substudy confirmed reductions in lean body mass alongside fat mass; adequate protein intake and resistance training are widely discussed as protective ^[4].
• Long-term unknowns. All pivotal outcome trials are ongoing; cardiovascular, renal, and long-term durability data do not yet exist ^[1].

Where it fits in metabolic research

Among the three compounds on this desk, retatrutide is the lead and the most data-rich — but all existing data come from Phase 2 trials in supervised settings. Its triple-receptor mechanism distinguishes it structurally from any approved incretin therapy, and the Phase 2 weight-loss magnitude is the largest reported for any pharmacological agent to date. Phase 3 TRIUMPH trials are ongoing, meaning the pivotal evidence is still accumulating. Read alongside MOTS-c, which works through the entirely different AMPK/mitochondrial axis, and tesamorelin, the desk's only approved compound, retatrutide illustrates the leading edge of incretin pharmacology before regulatory completion. See the comparison page for how it lines up against the others.